title: The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy.
abstract: Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s. Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia. Since the direct-acting antivirals were first approved in 2011 and then advanced in 2013, treatment-related ADEs and therapy discontinuations have rapidly decreased, while sustained virologic response rates have significantly increased. As the market for treating chronic HCV therapy has changed, so too has the ADE profile clinicians may need to manage.
authors.affiliation: a 1 University of the Sciences, Philadelphia College of Pharmacy, Department of Pharmacy Practice and Pharmacy Administration , Philadelphia, PA, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Smith
authors.affiliation: b 2 South Carolina College of Pharmacy, Clinical Pharmacy Specialist - GI/Hepatology, WJB Dorn VAMC, Department of Clinical Pharmacy and Outcomes Science , Columbia, SC, USA.
authors.forename: Bryan L
authors.initials: BL
authors.lastname: Love
authors.affiliation: c 3 University of Michigan College of Pharmacy, University of Michigan Health System, Department of Clinical Pharmacy , Ann Arbor, MI, USA rimam@med.umich.edu.
authors.forename: Rima A
authors.initials: RA
authors.lastname: Mohammad
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: adverse drug events; hepatitis C virus; ledipasvir; sofosbuvir